Navigation Links
Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
Date:5/31/2008

/2 clinical trials of XL765 as a single agent and in combination with other targeted agents or cytotoxic chemotherapy are planned to initiate later this year.

Investor and Analyst Briefing at ASCO, Monday, June 2, 6 p.m.

Exelixis will host an investor and analyst briefing on Monday, June 2, at 6:00 p.m. at the Hyatt McCormick Place (Regency C&D - 2nd Floor). At this event, Exelixis will provide a review of its data presented at ASCO and describe additional data on XL147, a PI3K inhibitor, and XL281, an inhibitor of RAF. The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com. An archived replay of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on July 2, 2008. Access numbers for this replay are: 1-888-286-8010 (domestic) and +1-617-801-6888 (international); the replay passcode is: 42662164.

About XL765

XL765 targets both PI3K and mTOR, key kinases in the PI3K signaling pathway. PI3K is a lipid kinase that plays a pivotal role in transmitting pro-mitotic and pro-survival signals in cells, and mTOR is a serine/threonine kinase that controls the protein translation machinery and hence, cell growth. PI3K is activated in human cancers by elevated receptor tyrosine kinase activity, by deletion of the tumor suppressor PTEN, or by mutation of its catalytic domain. mTOR is activated by growth factors via PI3K and AKT, but is also activated in a PI3K-independent fashion in response to nutrient and energy levels. Hence, targeting both PI3K and mTOR may provide additional benefit in some tumors compared with selectively targeting PI3K. In preclinical studies, XL765 has shown attractive pharmacokinetic and pharmacodynamic properties, and compelling efficacy in xenograft models, both as a single agent and in combination with other therapies.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology comp
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
9. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
10. Exelixis Announces First Quarter 2008 Financial Results
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... CHESTERBROOK, Pa. , July 31, 2014   ... a fully integrated specialty biopharmaceutical company, today announced that ... of 2014 on Thursday, August 7, 2014 before the ... will conduct a conference call that day at 8:30 ... second quarter of 2014. The presentation slides to be ...
(Date:7/31/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... of its lead molecule, Anatabine Citrate, in ... Clinical, The Translational Pharmaceutics Company, based in the ... early development programs. The Company expects to ... of the third quarter with the Medicines Healthcare products ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources Group ... market intelligence product Marketrack to now include ChinaTrack; the ... device landscape in an interactive dashboard providing detailed brand-level ... volumes at a hospital level. Other key ... Updated data feed: In addition to end-user surveys of ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
... , HOPKINTON, Mass., Nov. 2 Caliper Life Sciences, Inc. ... tools, presented at a training session for reviewers from the ... of the LabChip GX platform for high throughput screening and ... accept the FDA,s invitation to present our LabChip platform to ...
... This week begins American Diabetes Month® - a ... the launch of a new campaign by the American Diabetes ... and one of its National Strategic Partners, Liberty Medical Supply, ... give diabetes patients practical tips and advice for living with ...
Cached Medicine Technology:Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration 2Educational Video Series Released for American Diabetes Month 2Educational Video Series Released for American Diabetes Month 3Educational Video Series Released for American Diabetes Month 4
(Date:8/1/2014)... 1, 2014 (HealthDay News) -- Patients with the progressive, ... (COPD) have a new weapon to battle the disease, ... The agency approved a new treatment, an inhaled ... leading killer of Americans. COPD, which is often linked ... bronchitis and emphysema. Patients with COPD may ...
(Date:8/1/2014)... According to new market research ... North America, Europe, & ROW), by Vehicle Type ... (Gasoline & Diesel), by After-Treatment Device (DPF, DOC, ... Forecasts to 2019", defines and segments the global ... major countries in all the regions, and estimates ...
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 ... industry have benefited from innovative technologies that have ... resemble a patient's tooth color. Moreover, the burgeoning ... due to age-related tooth ailments. Due to long-term ... many elderly individuals have demanded dental fillings, veneers ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 ... Market Outlook to 2020", provides key market ... market. The report provides value, in millions ... average prices (in US dollars) within market ... Ultrasonic Generators and Argon Plasma Coagulation Generators. ...
(Date:8/1/2014)... Kathleen Doheny HealthDay Reporter ... control pills containing high doses of estrogen, along with ... cancer in women under 50, new preliminary research ... lead researcher Elisabeth Beaber, a staff scientist at the ... these formulations increase breast cancer risk while other formulations ...
Breaking Medicine News(10 mins):Health News:FDA Approves New Treatment for People With COPD 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 2Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 3Health News:Some Birth Control Pills May Up Breast Cancer Risk 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 3
... case of virgin birth in cartilaginous fish, after busting the mystery ... had only female sharks which had no contact with a male ... at Omaha's Henry Doorly Zoo, in the US, in December 2001 ... the female sharks in the aquarium. ,Female sharks have ...
... are in favour of a ban on smoking in workplaces ... ,Some 88 percent of citizens in the European Union ... a study by the European Commission, the bloc's executive arm. ... support for anti-tobacco policies could help make European public and ...
... the concerns of developing countries like Indonesia, the Unjted Nations ... efforts would be made to ensure "fair and equitable distribution ... of a pandemic." ,At the same time the ... WHO. ,A resolution on those lines ...
... a meeting of the U.N. General Assembly to review the ... it is possible to halt and reverse the spread of ... worldwide. ,U.N. member countries last year renewed pledges ... prevention, treatment and care services by 2010. In addition, one ...
... shown that a compound extracted from a plant from the ... and block its effect on the brain. ... Drug Abuse found that upon administration of the plant extract, ... tetrahydrocannabinol (THC), an active compound in marijuana. The treatment also ...
... in Vietnam confirmed Wednesday the possibility that a resident of ... contracted the lethal H5N1 strain of the bird flu virus, ... ,A fresh outbreak of bird flu has hit five provinces ... strain after being hospitalized in serious condition. ...
Cached Medicine News:Health News:WHO Announces Deal on Sharing Bird Flu Virus 2Health News:U.N. Secretary-General Ban Renews Goal To Reverse Spread of HIV by 2015 2Health News:Compound Present in Plant may Help to Curb Craving for Cannabis 2
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: